-+ 0.00%
-+ 0.00%
-+ 0.00%

HARBOUR BIOMED PARTNER, SOLSTICE ONCOLOGY, ANNOUNCES $225 MILLION SERIES A FINANCING TO ADVANCE PORUSTOBART, A NEOADJUVANT IMMUNO-ONCOLOGY THERAPY

路透·09/09/2026 11:12:48

登錄查看新聞詳情